

Clegg, Patsy PM SCC

From: De Jong, Geert G SI-HE/2
Sent: Saturday, October 14, 2000 4:33 AM
To: Owen, David DE SC-CHSE-DO
Cc: Clegg, Patsy PM SCC; Mallett, Anthony AK SC-CHSE-TM; Bradley, Scott SW SNZ-CHSE-SB
Subject: RE: Proposed epidemiological and human health studies in China

Importance: High
Sensitivity: Confidential

David

Thanks for your note. Please let me know as soon as you can when the meeting in EU will be held, in order to keep my diary free.
Best regards
Geert

From: Owen, David DE SC-CHSE-DO
Sent: 13 October 2000 18:00
To: De Jong, Geert G SI-HE/2
Cc: Clegg, Patsy PM SCC; Mallett, Anthony AK SC-CHSE-TM; Bradley, Scott SW SNZ-CHSE-SB
Subject: RE: Proposed epidemiological and human health studies in China
Sensitivity: Confidential

Geert,
Good to get you on board at this early stage. I would not expand the contact points at this time and until we have a more co-ordinated team in place .
There will be a meeting of interested parties in Houston next week and hopefully at a week later in Europe (no significance attached to regions, simply a matter of cost efficiency).
From there, there will be a link-up for both sides (hopefully APME will get in somewhere) and a global team proposed for furthering this work. Once this has been achieved, then other parties can be engaged.
I think this note makes sense!
Regards,
David.

David Owen, CHSE-DO

Manager, Health and Environmental Sciences
Shell Chemicals Limited., Shell Centre, London, SE1 7NA
Tel:(+44.171.934) 2288 Fax: 7627
Mobile: +44 (0)468.941106
Internet address:David.E.Owen@OPC.Shell.com

From: De Jong, Geert G SI-HE/2
Sent: 29 September 2000 06:39
To: Owen, David DE SC-CHSE-DO
Cc: Ransdell, Jerry JD SCC; Mallett, Anthony AK SC-CHSE-TM; Fraser, Alistair AE SHLOIL; Tsai, Shan SP SHLOIL-SPS; Priston, Robert RAJ SC-CHSE-BP; Clarke-Sturman, Tony A SIPC-OMF/4; Huisman, Bernard B SI-HE; Gaasbeek, Aart AP SI-PXE; Kulak, Linton L SCAN-HSSD; Steup, David R Alliance
Subject: RE: Proposed epidemiological and human health studies in China
Importance: High
Sensitivity: Confidential

David

I am happy to act as focal point on this issue and feed in any comments from various parties.
Should we involve / consult PXR? (Jeremy Frearson?)

Geert

From: Owen, David DE SC-CHSE-DO
Sent: 28 September 2000 18:46
To: De Jong, Geert G SI-HE/2
Cc: Ransdell, Jerry JD SCC; Mallett, Anthony AK SC-CHSE-TM; Fraser, Alistair AE SHLOIL; Tsai, Shan SP SHLOIL-SPS; Priston, Robert RAJ SC-CHSE-BP; Clarke-Sturman, Tony A SIPC-OMF/4; Huisman, Bernard B SI-HE; Gaasbeek, Aart AP SI-PXE; Kulak, Linton L SCAN-HSSD; Steup, David R Alliance
Subject: RE: Proposed epidemiological and human health studies in China
Sensitivity: Confidential

Geert,
Thanks for this input.
I have already made Tony (Mallett) aware that we must review the broader aspects of this China study. This will include Legal (already flagged) and Public Affairs considerations.
This will be an internal (Shell) debate. Tony will contact you next week. If there is feedback on this note from within the Health community can you act as focal point to feed into the discussions?
Regards,
David

David Owen, CHSE-DO

Manager, Health and Environmental Sciences
Shell Chemicals Limited., Shell Centre, London, SE1 7NA
Tel: (+44.171.934) 2288 Fax: 7627
Mobile: +44 (0)468.941106
Internet address: David.E.Owen@OPC.Shell.com

From: De Jong, Geert G SI-HE/2
Sent: 28 September 2000 16:22
To: Steup, David R Alliance
Cc: Ransdell, Jerry JD SCC; Mallett, Anthony AK SC-CHSE-TM; Owen, David DE SC-CHSE-DO; Fraser, Alistair AE SHLOIL; Tsai, Shan SP SHLOIL-SPS; Priston, Robert RAJ SC-CHSE-BP; Clarke-Sturman, Tony A SIPC-OMF/4; Huisman, Bernard B SI-HE; Gaasbeek, Aart AP SI-PXE; Kulak, Linton L SCAN-HSSD
Subject: Proposed epidemiological and human health studies in China
Importance: High
Sensitivity: Confidential

David,

I understand that you are the Alliance representative in the API benzene working group, which is involved in above project proposal.

I attended a presentation by Dr. Pat Beathy (Chevron) and Dr. Rob Schnatter (Exxon Mobil), which was held on 26th September at CONCAWE offices in Brussels. I attended as member of the CONCAWE Health Management Group. Tony Mallett attended on behalf of Shell Chemicals London.

It is obvious that the studies provide an unique opportunity to examine health effects among highly exposed benzene workers in China.

The scientific aspects of the studies, as well as the potential benefits (to the oil / chemical industry in the USA and Europe viz-a-viz regulatory developments etc.) were well explained. The total cost of the project would be about 7 million

US\$ (during a 5 years study period).

However, there are important ethical considerations. The presenters were aware of (most of?) these considerations and they indicated how these would be addressed. However, a detailed plan on how these are going to be addressed is not available.

Some other aspects may not have been examined carefully enough by the researchers, including the following:

- what are the benefits to the community in China? (in addition to the laboratory which is already being set up in Shanghai)
 - what is the Chinese component of the overall project (in other words how much will be invested in China, how much for the researchers in the USA)
 - how will the study help to improve working conditions (in a sustainable manner).
 - is there a plan with clear deliverables etc. addressing this?
 - how will the study contribute to local capacity building (apart from training of some local lab technicians)
 - how will the study help to improve occupational health management and infrastructure in China etc.
- etc.

Potential reputation issues have insufficiently been addressed so far, in my view.

I have discussed this amongst others with Dr Gordon Ebbon of Texaco Europe. He will raise the issue through his channels in Texaco.

Above considerations are probably not new. The reason to alert you and others is mainly to make sure that various interested parties in Shell get involved in the discussion and that we come up with a common point of view when individual business sectors are approached with the request to sponsor the study.

Tony Mallett will be setting up a meeting within the next few weeks to discuss the 'chemicals' view on the proposed studies.

Your comments and of those copied are most welcome,

kind regards
Geert de Jong
Shell International Health Services (SI-HE/2)
The Hague
tel.: +31 70 377 2516
mobile: +31 6 55 124123